Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018The Neuropathic Pain Market is Forecast to Show Significant Growth until 2018
By: Rajesh Gunnam • Increasing patient pool for neuropathic pain due to the increase in the prevalence of co-morbid conditions, such as herpes zoster, multiple sclerosis, trigeminal neuralgia, diabetes and migraine. • Clinical development and preferential uptake of newer disease modifying agents, such as Zenvia (AVP-923) and AS-3201 (ranirestat) GlobalData analysis suggests that the current competition in the neuropathic pain market is strong, led by Pfizer’s Lyrica and Eli Lilly’s Cymbalta. There are only five drugs that are approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of neuropathic pain: Lyrica (pregabalin) (approved under the trade name Versatis in Europe) and recently, Qutenza (capsaicin 8% patch). Lyrica, Cymbalta, Lidoderm and Qutenza currently have a significant presence in the market. Moreover, the presence of gabapentin and other generic drugs has intensified the competition. Pfizer remains the market leader in the neuropathic pain market, followed by Eli Lilly. There is competition between Lyrica and Cymbalta in the treatment of pain associated with diabetic peripheral neuropathy (DPN) GlobataData’ therapies. The currently available therapies provide partial pain relief to the patient instead of eradicating the underlying cause of the pain. Although the current market is reasonably well served, the market still needs disease modifying therapies offering better results in terms of safety and efficacy, as well as a cure for the underlying cause of the pain. Achieving these objectives will address the existing unmet need in the market. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ GlobalData found that the available treatment options are moderately successful in meeting the market demand. Although the current neuropathic pain therapeutics market has FDA approved drugs such as SNRIs (serotonin–norepinephrine re-uptake inhibitors) and tricyclic antidepressants (TCAs), these drugs only have moderate efficacy and safety profiles. The current therapies are competing to provide a greater than or equal to 50% reduction in pain. A greater than or equal to 30% reduction in pain is considered to be clinically significant. Providing partial relief (a greater than or equal to 50% reduction in pain) has been the target endpoint for products in the market. However, there is a need for a product that can be more efficacious in reducing the pain, offering long term pain relief with better safety. There is potential in the market for any new entrant that will cater to these unmet needs and there is enormous opportunity for any drug that can offer better long-term efficacy and safety. GlobalData, the industry analysis specialist, has released its new report, “Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global neuropathic pain therapeutics market. The report identifies the key trends shaping and driving the global neuropathic pain therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global chronic pain sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number